WebJan 10, 2024 · C4 Therapeutics, Inc. January 10, 2024, 7:00 AM · 7 min read. – Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2024–. – IND Clearance Achieved for CFT8634, a ... WebCFT7455 (100 µg/kg) led to tumor regression. Together these results show that the optimized CRBN binding and catalytic activity of CFT7455 results in rapid, deep and sustained degradation of IKZF1/3 and translates to tumor regressions in NHL models. Conclusions: CFT7455 is a potent, selective catalytic degrader of

【CFT7455】CFT7455 CAS号:2504235-67-8【结构式 性质 活性】

WebThese preclinical data show that BTX-1188 is a promising drug candidate for AML and other tumor types. Its immunomodulatory properties owing to IKZF1/3 degradation may … WebCFT7455: C4疗法: Ikaros/Aiolos (IKZF1/3) 降解剂: 多发性骨髓瘤和淋巴瘤: 2024 年上半年第一阶段 ford f450 custom 2012

C4 Therapeutics Announces 2024 Key Milestones to Advance

WebThese preclinical data show that BTX-1188 is a promising drug candidate for AML and other tumor types. Its immunomodulatory properties owing to IKZF1/3 degradation may prevent systemic inflammatory dose-limiting toxicities associated with pure GSPT1 degradation (Uy 2024). BTX-1188 has entered phase 1 clinical studies for advanced solid tumors ... WebThe U.S. Food and Drug Administration (FDA) announced the clearance of the Investigational New Drug Application of CFT7455, a monofunctional degradation activating compound (monoDAC) that targets IKZF1/3. 1 This orally available compound is designed to treat multiple myeloma (MM) and non-Hodgkin lymphomas (NHLs). CFT7455 as a … WebCFT7455 is designed to be highly potent and selective against its intended targets, IKZF1/3. The Phase 1/2 trial is designed to primarily investigate safety, tolerability, and anti-tumor … ford f450 diecast